Abstract
Combinations of 5-fluorouracil (5-FU) and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 11 long-term stabilizations were observed. No unexpected toxicity occurred.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Schlumberger, M., Abdelmoumene, N., Delisle, M. et al. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. Br J Cancer 71, 363–365 (1995). https://doi.org/10.1038/bjc.1995.73
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.73
- Springer Nature Limited
This article is cited by
-
Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities
Reviews in Endocrine and Metabolic Disorders (2024)
-
Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer
Thyroid Research (2022)
-
Using molecular dynamics simulation to explore the binding of the three potent anticancer drugs sorafenib, streptozotocin, and sunitinib to functionalized carbon nanotubes
Journal of Molecular Modeling (2019)
-
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers
BMC Cancer (2014)
-
Neues zur systemischen Therapie des medullären Schilddrüsenkarzinoms
Der Onkologe (2013)